Bioceres Crop Solutions Statistics

Total Valuation

BCBA:BIOX has a market cap or net worth of ARS 137.40 billion. The enterprise value is 529.18 billion.

Market Cap	137.40B
Enterprise Value	529.18B

Important Dates

The last earnings date was Thursday, November 13, 2025.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.18%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	1.31%
Owned by Institutions (%)	15.21%
Float	33.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.32
PB Ratio	0.35
P/TBV Ratio	n/a
P/FCF Ratio	1.85
P/OCF Ratio	1.70
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.71, with an EV/FCF ratio of 7.14.

EV / Earnings	-6.85
EV / Sales	1.15
EV / EBITDA	21.71
EV / EBIT	n/a
EV / FCF	7.14

Financial Position

The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.90.

Current Ratio	0.94
Quick Ratio	0.62
Debt / Equity	0.90
Debt / EBITDA	15.08
Debt / FCF	4.78
Interest Coverage	-0.17

Financial Efficiency

Return on equity (ROE) is -18.95% and return on invested capital (ROIC) is -0.53%.

Return on Equity (ROE)	-18.95%
Return on Assets (ROA)	-0.39%
Return on Invested Capital (ROIC)	-0.53%
Return on Capital Employed (ROCE)	-1.13%
Revenue Per Employee	580.61M
Profits Per Employee	-102.88M
Employee Count	751
Asset Turnover	0.41
Inventory Turnover	1.84

Taxes

In the past 12 months, BCBA:BIOX has paid 6.34 billion in taxes.

Income Tax	6.34B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -66.96% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-66.96%
50-Day Moving Average	2,501.64
200-Day Moving Average	4,402.08
Relative Strength Index (RSI)	44.80
Average Volume (20 Days)	149,415

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.10

Income Statement

In the last 12 months, BCBA:BIOX had revenue of ARS 436.04 billion and -77.26 billion in losses. Loss per share was -1,219.16.

Revenue	436.04B
Gross Profit	171.90B
Operating Income	-6.72B
Pretax Income	-76.02B
Net Income	-77.26B
EBITDA	16.18B
EBIT	-6.72B
Loss Per Share	-1,219.16

Full Income Statement

Balance Sheet

The company has 22.77 billion in cash and 354.21 billion in debt, giving a net cash position of -331.44 billion.

Cash & Cash Equivalents	22.77B
Total Debt	354.21B
Net Cash	-331.44B
Net Cash Per Share	n/a
Equity (Book Value)	395.15B
Book Value Per Share	5,584.56
Working Capital	-22.70B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 81.03 billion and capital expenditures -6.90 billion, giving a free cash flow of 74.13 billion.

Operating Cash Flow	81.03B
Capital Expenditures	-6.90B
Free Cash Flow	74.13B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 39.42%, with operating and profit margins of -1.54% and -17.72%.

Gross Margin	39.42%
Operating Margin	-1.54%
Pretax Margin	-17.44%
Profit Margin	-17.72%
EBITDA Margin	3.71%
EBIT Margin	-1.54%
FCF Margin	17.00%

Dividends & Yields

BCBA:BIOX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.18%
Shareholder Yield	0.18%
Earnings Yield	-56.23%
FCF Yield	53.95%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 24, 2024. It was a forward split with a ratio of 2.

Last Split Date	Jan 24, 2024
Split Type	Forward
Split Ratio	2

Scores

BCBA:BIOX has an Altman Z-Score of 0.66 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.66
Piotroski F-Score	3